Evidence map›Paper›PMID 19183461›Full record

ArticleBMC medical genetics2009

SLC6A3 and body mass index in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.

Elizabeth M Azzato, Lindsay M Morton, Andrew W Bergen, Sophia S Wang, Nilanjan Chatterjee, Paul Kvale, Meredith Yeager, Richard B Hayes, Stephen J Chanock, Neil E Caporaso

Open access · goldAbstract read
In one paragraph

Article in BMC medical genetics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Observational
  5. Dopamine transporter gene variant affecting expression in human brain is associated with bipolar disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2011
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

Elizabeth M AzzatoDivision of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Rockville, Maryland, USA. ema32@cam.ac.uk
Lindsay M Morton
Andrew W Bergen
Sophia S Wang
Nilanjan Chatterjee
Paul Kvale
Meredith Yeager
Richard B Hayes
Stephen J Chanock
Neil E Caporaso
United States Department of Health and Human Services · USDivision of Cancer Epidemiology and GeneticsNational Cancer Institute · USHenry Ford Health System · USScience Applications International Corporation (United States) · USSRI International · US

Funding

University of Toronto Coordinating Genetics Core & Clinical Trial SiteU01DA020830 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI SWAN, GARY E · 2005 to 2014
$22.4M
NCI NIH HHS N01 CO012400NCI NIH HHS N01-CO-12400NIDA NIH HHS U01 DA020830
6 · The paper itself

Abstract

backgroundTo investigate the contribution of the dopamine transporter to dopaminergic reward-related behaviors and anthropometry, we evaluated associations between polymorphisms at the dopamine transporter gene(SLC6A3) and body mass index (BMI), among participants in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.

methodsFour polymorphisms (rs6350, rs6413429, rs6347 and the 3' variable number of tandem repeat (3' VNTR) polymorphism) at the SLC6A3 gene were genotyped in 2,364 participants selected from the screening arm of PLCO randomly within strata of sex, age and smoking history. Height and weight at ages 20 and 50 years and baseline were assessed by questionnaire. BMI was calculated and categorized as underweight, normal, overweight and obese (<18.5, 18.5-24.9, 25.0-29.9, or > or = 30 kg/m2, respectively). Odds ratios (ORs) and 95% confidence intervals (CIs) of SLC6A3 genotypes and haplotypes were computed using conditional logistic regression.

resultsCompared with individuals having a normal BMI, obese individuals at the time of the baseline study questionnaire were less likely to possess the 3' VNTR variant allele with 9 copies of the repeated sequence in a dose-dependent model (** is referent; OR*9 = 0.80, OR99 = 0.47, Ptrend = 0.005). Compared with individuals having a normal BMI at age 50, overweight individuals (A-C-G-* is referent; ORA-C-G-9 = 0.80, 95% CI 0.65-0.99, p = 0.04) and obese individuals (A-C-G-* is referent; ORA-C-G-9 = 0.70, 95% CI 0.49-0.99, p = 0.04) were less likely to possess the haplotype with the 3'variant allele (A-C-G-9).

conclusionOur results support a role of genetic variation at the dopamine transporter gene, SLC6A3, as a modifier of BMI.

Indexed as

Body Mass IndexAgedAllelesCross-Sectional StudiesDopamine Plasma Membrane Transport ProteinsFemaleGene FrequencyGenotypeHumansLikelihood FunctionsMaleMiddle AgedMinisatellite RepeatsOverweightPolymorphism, Single NucleotideDopamine Plasma Membrane Transport ProteinsSLC6A3 protein, human

Identifiers

PMID19183461
PMCPMC2640369
OpenAlexW2128036852

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.